Pfizer Inc today announced that it has voluntarily recalled 14 lots of Lo/Ovral^®-28 (norgestrel and ethinyl estradiol) Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets- oral contraceptives indicated for the prevention of pregnancy in women. After conducting an investigation, Pfizer discovered that these products could leave unsuspecting women without adequate contraception and at risk for unintended pregnancy. Pfizer explains that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence.

These products are distributed to warehouses, clinics and retail pharmacies nationwide.  Pfizer advises that consumers exposed to the affected packaging begin using a non-hormonal form of contraception immediately, notify their physician and return the product to the pharmacy. According to its representatives, Pfizer is not providing refunds to purchasers of the products.

For a complete list of the Lot numbers of the recalled packs of Lo/Ovral®-28 (norgestrel and ethinyl estradiol) Tablets and Norgestrel and Ethinyl Estradiol Tablets (generic), go to Pfizer's press release here.

If you are interested in discussing your rights as a purchaser of Lo/Ovral®-28 (norgestrel and ethinyl estradiol) Tablets and Norgestrel and Ethinyl Estradiol Tablets (generic), or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .